Published in J Chromatogr A on August 15, 2003
Analysis of low-abundance, low-molecular-weight serum proteins using mass spectrometry. J Biomol Tech (2004) 1.48
Proteomics: challenges, techniques and possibilities to overcome biological sample complexity. Hum Genomics Proteomics (2009) 1.07
Assessment of albumin removal from an immunoaffinity spin column: critical implications for proteomic examination of the albuminome and albumin-depleted samples. Proteomics (2009) 1.05
High abundance proteins depletion vs low abundance proteins enrichment: comparison of methods to reduce the plasma proteome complexity. PLoS One (2011) 0.99
Selective enrichment and sensitive detection of peptide and protein biomarkers in human serum using polymeric reverse micelles and MALDI-MS. Analyst (2011) 0.84
Novel and unique diagnostic biomarkers for Bacillus anthracis infection. Appl Environ Microbiol (2009) 0.80
Plasma proteomic profile of sulfur mustard exposed lung diseases patients using 2-dimensional gel electrophoresis. Clin Proteomics (2011) 0.78
Analysis of differentially expressed proteins in cancerous and normal colonic tissues. World J Gastroenterol (2006) 0.78
Proteomic analysis of colorectal cancer: prefractionation strategies using two-dimensional free-flow electrophoresis. Comp Funct Genomics (2005) 0.76
Depletion of plasma albumin for proteomic analysis of Bothrops jararaca snake plasma. J Biomol Tech (2011) 0.75
Endogenous plasma Peptide detection and identification in the rat by a combination of fractionation methods and mass spectrometry. Biomark Insights (2007) 0.75
Formation of arrowhead complexes with heavy meromyosin in a variety of cell types. J Cell Biol (1969) 13.82
Mitosis and intermediate-sized filaments in developing skeletal muscle. J Cell Biol (1968) 5.78
Mitosis and the processes of differentiation of myogenic cells in vitro. J Cell Biol (1969) 2.96
Proliferation of muscle satellite cells on intact myofibers in culture. Dev Biol (1986) 2.91
Inhibition of myoblast fusion after one round of DNA synthesis in 5-bromodeoxyuridine. J Cell Biol (1970) 2.84
Neutral amino acid transport by membrane vesicles of Streptococcus cremoris is subject to regulation by internal pH. J Bacteriol (1987) 2.44
Elimination of uninformative variables for multivariate calibration. Anal Chem (1996) 2.30
Identification of a heparin-binding hemagglutinin present in mycobacteria. J Exp Med (1996) 2.18
Physiology and pathophysiology of matrix metalloproteases. Amino Acids (2010) 1.83
Molecular characterization of the mycobacterial heparin-binding hemagglutinin, a mycobacterial adhesin. Proc Natl Acad Sci U S A (1998) 1.76
Transport of branched-chain amino acids in membrane vesicles of Streptococcus cremoris. J Bacteriol (1987) 1.72
Modest effect of p53, EGFR and HER-2/neu on prognosis in epithelial ovarian cancer: a meta-analysis. Br J Cancer (2009) 1.53
Plasma membranes from cultured muscle cells: isolation procedure and separation of putative plasma-membrane marker enzymes. Proc Natl Acad Sci U S A (1973) 1.50
Regeneration of single skeletal muscle fibers in vitro. Anat Rec (1975) 1.49
Enzymatic liberation of myogenic cells from adult rat muscle. Anat Rec (1974) 1.44
The effect of mitotic inhibitors in myogenesis in vitro. J Cell Biol (1968) 1.43
A satellite cell mitogen from crushed adult muscle. Dev Biol (1986) 1.43
Oestrogen replacement therapy lowers plasma levels of asymmetrical dimethylarginine in healthy postmenopausal women. Clin Sci (Lond) (2003) 1.43
Large-amplitude spin dynamics driven by a THz pulse in resonance with an electromagnon. Science (2014) 1.41
[Surgical treatment of early-stage vulva carcinoma and the complications of the operation]. Ned Tijdschr Geneeskd (2005) 1.41
Residual infrarenal aortic neck following endovascular and open aneurysm repair. Eur J Vasc Endovasc Surg (2012) 1.38
Intraoperative near-infrared fluorescence imaging for sentinel lymph node detection in vulvar cancer: first clinical results. Gynecol Oncol (2010) 1.38
The clinical trail of TRAIL. Eur J Cancer (2006) 1.35
Nanoscale spin reversal by non-local angular momentum transfer following ultrafast laser excitation in ferrimagnetic GdFeCo. Nat Mater (2013) 1.31
A four-gene methylation marker panel as triage test in high-risk human papillomavirus positive patients. Int J Cancer (2012) 1.28
Telomere length in breast cancer patients before and after chemotherapy with or without stem cell transplantation. Br J Cancer (2001) 1.28
Non-canonical kinase signaling by the death ligand TRAIL in cancer cells: discord in the death receptor family. Cell Death Differ (2013) 1.27
Surgery and radiotherapy in vulvar cancer. Crit Rev Oncol Hematol (2006) 1.24
MEIS and PBX homeobox proteins in ovarian cancer. Eur J Cancer (2007) 1.19
P-glycoprotein expression and DNA topoisomerase I and II activity in benign tumors of the ovary and in malignant tumors of the ovary, before and after platinum/cyclophosphamide chemotherapy. Cancer Res (1991) 1.16
Presence of tumor-infiltrating lymphocytes is an independent prognostic factor in type I and II endometrial cancer. Gynecol Oncol (2009) 1.16
Non-steroidal anti-inflammatory drugs to potentiate chemotherapy effects: from lab to clinic. Crit Rev Oncol Hematol (2006) 1.16
The ErbB signalling pathway: protein expression and prognostic value in epithelial ovarian cancer. Br J Cancer (2008) 1.15
Soluble TRAIL concentrations are raised in patients with systemic lupus erythematosus. Ann Rheum Dis (2004) 1.13
Negative electrospray ionization mass spectrometry of synthetic and chemically modified oligonucleotides. Nucleic Acids Res (1994) 1.11
TRAIL receptor targeting therapies for non-small cell lung cancer: current status and perspectives. Drug Resist Updat (2009) 1.11
Death receptors and ligands in cervical carcinogenesis: an immunohistochemical study. Gynecol Oncol (2005) 1.08
Changes in apoptosis during the development of colorectal cancer: a systematic review of the literature. Crit Rev Oncol Hematol (2003) 1.08
Inhibition of activated protein C by recombinant alpha 1-antitrypsin variants with substitution of arginine or leucine for methionine358. J Biol Chem (1990) 1.08
Bortezomib and TRAIL: a perfect match for apoptotic elimination of tumour cells? Crit Rev Oncol Hematol (2012) 1.08
Genetic transfer of non-P-glycoprotein-mediated multidrug resistance (MDR) in somatic cell fusion: dissection of a compound MDR phenotype. Proc Natl Acad Sci U S A (1992) 1.08
Acid mucopolysaccharide synthesis by chick amnion cell cultures. Inhibition by 5-bromodeoxyuridine. Exp Cell Res (1971) 1.06
Disruption of the MDM2-p53 interaction strongly potentiates p53-dependent apoptosis in cisplatin-resistant human testicular carcinoma cells via the Fas/FasL pathway. Cell Death Dis (2011) 1.04
Factors influencing p53 expression in ovarian cancer as a biomarker of clinical outcome in multicentre studies. Br J Cancer (2006) 1.01
Granulosa cell tumors of the ovary: the clinical value of serum inhibin A and B levels in a large single center cohort. Gynecol Oncol (2007) 1.01
tRNA separation by high-performance liquid chromatography using an aggregate of ODS-Hypersil and trioctylmethylammonium chloride. J Chromatogr (1983) 1.01
Risk factors for short- and long-term complications after groin surgery in vulvar cancer. Br J Cancer (2011) 1.00
Management of vulvar cancers. Eur J Surg Oncol (2006) 0.99
A novel insect defensin mediates the inducible antibacterial activity in larvae of the dragonfly Aeschna cyanea (Paleoptera, Odonata). Eur J Biochem (1992) 0.99
Interleukin-10 and Fas polymorphisms and susceptibility for (pre)neoplastic cervical disease. Int J Gynecol Cancer (2005) 0.96
Telomerase activity as a biomarker for (pre)neoplastic cervical disease in scrapings and frozen sections from patients with abnormal cervical smear. J Clin Oncol (1998) 0.96
Changes in fat cell size and in vitro lipolytic activity of abdominal and gluteal adipocytes after a one-year cross-sex hormone administration in transsexuals. Metabolism (1999) 0.96
Molecular prognostic markers in ovarian cancer: toward patient-tailored therapy. Int J Gynecol Cancer (2006) 0.95
Differentiation of creatine phosphokinase during myogenesis: quantitative fractionation of isozymes. Dev Biol (1977) 0.95
Network analysis of positional candidate genes of schizophrenia highlights myelin-related pathways. Mol Psychiatry (2009) 0.95
Immunofluorescent and histochemical localization of AMP deaminase in skeletal muscle. J Cell Biol (1979) 0.95
Identification of genes and pathways associated with cytotoxic T lymphocyte infiltration of serous ovarian cancer. Br J Cancer (2010) 0.95
Telomerase in relation to clinicopathologic prognostic factors and survival in cervical cancer. Int J Cancer (2001) 0.95
Differential sensitivity to 5-bromodeoxyuridine during the S phase of synchronized myogenic cells. Dev Biol (1976) 0.94
Detection of cervical neoplasia by DNA methylation analysis in cervico-vaginal lavages, a feasibility study. Gynecol Oncol (2010) 0.94
Epitopes on CA 125 from cervical mucus and ascites fluid and characterization of six new antibodies. Third report from the ISOBM TD-1 workshop. Tumour Biol (2003) 0.93
Examination of fatigue development in elite soccer in a hot environment: a multi-experimental approach. Scand J Med Sci Sports (2010) 0.93
Analysis of human serum by liquid chromatography-mass spectrometry: improved sample preparation and data analysis. J Chromatogr A (2006) 0.92
Targeting TRAIL death receptors. Curr Opin Pharmacol (2008) 0.92
A comparison of quality of life between vulvar cancer patients after sentinel lymph node procedure only and inguinofemoral lymphadenectomy. Gynecol Oncol (2009) 0.92
Patterns of care in surgery for ovarian cancer in Europe. Eur J Surg Oncol (2010) 0.92
Analysis of recombinant Schistosoma mansoni antigen rSmp28 by on-line liquid chromatography-mass spectrometry combined with sodium dodecyl sulfate polyacrylamide gel electrophoresis. Anal Biochem (1994) 0.92
Drug-induced caspase 8 upregulation sensitises cisplatin-resistant ovarian carcinoma cells to rhTRAIL-induced apoptosis. Br J Cancer (2011) 0.92
Anticancer drugs aimed at E6 and E7 activity in HPV-positive cervical cancer. Curr Cancer Drug Targets (2012) 0.91
Differential modulation of the TRAIL receptors and the CD95 receptor in colon carcinoma cell lines. Br J Cancer (2003) 0.91
Protein mapping by two-dimensional high performance liquid chromatography. J Chromatogr A (2000) 0.90
Mathematical modelling of insect neuropeptide potencies. Are quantitatively predictive models possible? Insect Biochem Mol Biol (2000) 0.90
Nutlin-3 preferentially sensitises wild-type p53-expressing cancer cells to DR5-selective TRAIL over rhTRAIL. Br J Cancer (2013) 0.90
EGFR expression is associated with groin node metastases in vulvar cancer, but does not improve their prediction. Gynecol Oncol (2006) 0.89
Cytotoxicity of rhein, the active metabolite of sennoside laxatives, is reduced by multidrug resistance-associated protein 1. Br J Cancer (2002) 0.88
Activity-based enrichment of matrix metalloproteinases using reversible inhibitors as affinity ligands. J Chromatogr A (2003) 0.88
Human hybridoma cells produced by electro-fusion. FEBS Lett (1982) 0.88
Reactivity of alpha 1-antitrypsin mutants against proteolytic enzymes of the kallikrein-kinin, complement, and fibrinolytic systems. J Biol Chem (1990) 0.88
DNA-phospholipid recognition: modulation by metal ion and lipid nature. Complexes structure and stability calculated by molecular mechanics. Bioelectrochemistry (2002) 0.87
Long-term morbidity of adjuvant whole abdominal radiotherapy (WART) or chemotherapy for early stage ovarian cancer. Eur J Cancer (2009) 0.87
DNA topoisomerase IIalpha and -beta expression in human ovarian cancer. Br J Cancer (1999) 0.86
Analysis of the entire HLA region in susceptibility for cervical cancer: a comprehensive study. J Med Genet (2005) 0.86
Dysplasia in fundic gland polyps is associated with nuclear beta-catenin expression and relatively high cell turnover rates. Scand J Gastroenterol (2003) 0.86
Detection of telomerase, its components, and human papillomavirus in cervical scrapings as a tool for triage in women with cervical dysplasia. J Clin Pathol (2003) 0.86
Modulation of death receptor pathways in oncology. Drugs Today (Barc) (2003) 0.86